Finasteride: What to Expect Week by Week in Your First Month

How Finasteride Works: The Biochemistry Behind Month One

Finasteride blocks the type II isoform of 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the androgen primarily responsible for miniaturizing genetically susceptible follicles in androgenetic alopecia. By cutting scalp DHT by approximately 60 to 70%, finasteride removes the dominant driver of follicle shrinkage before any hair you can see actually changes [1].

This is the core reason month one looks uneventful on the outside. The drug is doing real work at the receptor level while your visible hair count remains static or slightly lower because of normal cycle turnover.

DHT Suppression: How Fast Does It Happen?

Finasteride reaches steady-state plasma concentrations in 3 to 5 days at the 1 mg daily dose [2]. Serum DHT begins falling within 24 hours of the first tablet. By day 7, scalp and serum DHT suppression is already close to the plateau seen at 12 months. A crossover pharmacokinetic study published in the Journal of Clinical Pharmacology confirmed that the enzyme inhibition is not meaningfully dose-dependent above 0.2 mg, meaning 1 mg is well above the threshold needed for maximum type II inhibition [3].

What the Follicle Cycle Means for Month One

Human hair follicles cycle through anagen (growth, 2 to 7 years), catagen (transition, 2 to 3 weeks), and telogen (rest/shedding, 3 to 4 months). When DHT suppression begins, follicles that were mid-miniaturization do not immediately reverse. They finish their current cycle first. This lag is why the Kaufman et al. 5-year trial (N=1,553 men) recorded no statistically significant hair-count improvement at 3 months, yet showed a mean increase of 107 hairs per 1-inch circle by month 12 compared to placebo [1].

Month one sits entirely inside that lag window. Nothing visible is expected. That is normal physiology, not treatment failure.

Week-by-Week Breakdown: Days 1 Through 30

Week 1 (Days 1 to 7): Biochemistry Shifts, Nothing Visible Yet

The first tablet suppresses roughly half of circulating DHT within the first day [2]. By day 5 you are at pharmacokinetic steady state. You will not see or feel anything different on your scalp. Some men report a very mild scalp sensation or slight oiliness change in the first week, but no controlled trial has validated this as a consistent pharmacological effect rather than expectation bias.

If you were asked to take a baseline PSA (prostate-specific antigen), do it before this week ends. Finasteride reduces PSA by approximately 50% after 6 months of use [4]. Any PSA drawn after starting the drug needs to be doubled to approximate true prostate volume, per the American Urological Association guidelines [4].

Week 1 action items: take the pill at the same time each day, photograph your hairline and crown under consistent lighting, and log your baseline.

Week 2 (Days 8 to 14): The Possible Early Shed Begins

Some men notice slightly more hairs on the shower drain or pillow starting around day 10 to 14. This is called a telogen effluvium-type response and it happens because newly DHT-deprived follicles shift cycling dynamics. Follicles that were prolonged in a thinning telogen phase may now release those hairs as the follicle prepares to re-enter a healthier anagen [5].

This shedding is not universal. A minority of users experience it. When it does occur, it typically resolves within 4 to 12 weeks [5]. Seeing 10 to 20 extra hairs per day is within normal range; losing dense clumps is not and warrants a clinical call.

Week 3 (Days 15 to 21): Scalp Environment Stabilizing

By the third week, DHT suppression is at or near its maximum effect for the 1 mg dose. The scalp microenvironment is measurably different from baseline even if you cannot see it. Studies using scalp biopsy at 12 months in AGA patients on finasteride show an increase in the anagen-to-telogen follicle ratio, but that histological shift takes months to manifest [1].

Side effects, if they are going to appear, most commonly surface in this first 1 to 4 week window. The key two-year trial published in JAMA Dermatology (Finasteride Male Pattern Hair Loss Study Group, N=1,553) reported decreased libido in 1.8% of finasteride users vs 1.3% placebo, and erectile dysfunction in 1.3% vs 0.7% placebo at the one-year mark [1]. Most cases resolved with continued use or within weeks of discontinuation.

Week 4 (Days 22 to 30): End of Month One Checkpoint

You have completed 30 days of consistent DHT suppression. Your scalp DHT is 60 to 70% lower than it was on day zero [2]. Your hair looks the same or possibly slightly thinner due to any shedding phase. Both outcomes are consistent with treatment proceeding correctly.

This is also the right time to assess tolerability. Sexual side effects that persist beyond 4 weeks should be discussed with your prescriber. A 2019 systematic review in JAMA Dermatology (Mella et al.) found that persistent post-finasteride sexual dysfunction beyond 3 months occurred in fewer than 1% of study participants across randomized trials, though individual case reports describe longer durations [6].

The HealthRX Month-One Checkpoint Framework: At day 30, evaluate three things only. First, tolerability (no persistent side effects). Second, adherence (did you miss fewer than 3 doses?). Third, baseline documentation (do you have photos and, if applicable, a pre-treatment PSA?). Visible efficacy is not a valid month-one endpoint and should not drive any decision to continue or stop.

What the Clinical Evidence Says About Early Finasteride Use

The Kaufman et al. 5-year data (N=1,553) remains the foundational reference for AGA treatment duration expectations [1]. Key findings from that trial:

• At 1 year, 83% of finasteride users maintained or increased hair count vs 28% in the placebo group.
• At 2 years, mean hair count in the finasteride group was 138 hairs per 1-inch circle above the placebo group.
• At 5 years, 48% of finasteride users showed visible improvement vs continued decline in 75% of placebo users.

None of those endpoints exist at month one. The trial explicitly noted that the earliest statistically significant divergence from placebo in hair count appeared between months 3 and 6 [1].

A separate pharmacodynamic study by Andriole et al. (published in Urology, examining the 5 mg BPH dose but applicable for mechanism) confirmed that DHT suppression magnitude is consistent from week 1 onward and does not "build up" further with time [7]. The suppression is immediate. The follicle response is slow. Those two facts together define the entire first-month experience.

The Shedding Question: Is It a Good Sign?

Some online sources frame the early shed as proof the drug is working. The honest clinical answer is more nuanced. Shedding does reflect a DHT-driven follicle cycle reset, which is mechanistically consistent with finasteride activity [5]. A study in the Journal of Investigative Dermatology found that follicles transitioning from a prolonged dystrophic telogen to healthy anagen do release telogen hairs first [5].

However, absence of shedding does not mean the drug is not working. Most men in the Kaufman trial did not report a noticeable early shed and still achieved the trial's positive hair-count outcomes [1]. Do not interpret no shedding as a failure signal.

Comparing Finasteride to Minoxidil in Month One

Minoxidil, the other first-line AGA therapy, works via a different pathway: it prolongs anagen and increases follicle size through vasodilation and potassium channel opening [8]. The two agents are often combined. In month one, minoxidil is also unlikely to show visible results, and it carries its own early shedding period. A 2021 network meta-analysis in JAMA Dermatology ranked oral minoxidil plus finasteride as the most effective combination for AGA across 30 randomized trials, but combination therapy decisions belong in a clinical conversation, not a self-directed month-one protocol [8].

Side Effects: What Is Real, What Is Rare, and When to Call

Sexual Side Effects

The most discussed finasteride side effects are sexual: decreased libido, erectile dysfunction, and ejaculatory changes. The key registration trial data show these occur in approximately 3.8% of finasteride users vs 2.1% of placebo users [1]. The absolute difference is 1.7 percentage points.

"The sexual adverse effects reported in clinical trials of finasteride 1 mg were generally mild and resolved in most men who continued therapy or discontinued the drug," according to the FDA prescribing information for Propecia [2]. That statement reflects the trial-level data but does not rule out rare persistent cases.

The post-finasteride syndrome (PFS) debate involves reports of persistent sexual, neurological, and psychological symptoms after stopping finasteride. The FDA added a label update in 2012 noting rare reports of persistent sexual dysfunction [2]. Prevalence estimates from retrospective case series are methodologically limited by selection bias. Men with concerns about PFS should review the 2020 European Academy of Dermatology and Venereology (EADV) guidelines, which note the condition is recognized but poorly characterized in controlled data [9].

Non-Sexual Side Effects

Gynecomastia (breast tissue enlargement) occurs in fewer than 1% of users per trial data [1]. Testicular pain and hypersensitivity reactions are listed in post-marketing reports [2]. Finasteride also reduces PSA by 50%, which is not a side effect but a known drug effect that requires clinical awareness for prostate cancer screening [4].

Mental Health Signals

A 2020 cohort study by Dyson et al. In BMJ Open Surgery found a modest association between finasteride use and depression in a retrospective claims analysis, though confounding by the psychosocial burden of hair loss itself was acknowledged as a significant limitation [10]. Men with a history of depression should discuss this signal with their prescriber before starting.

Practical Guidance for Month One

Dosing and Timing

Finasteride 1 mg is taken once daily with or without food. The half-life is 6 to 8 hours, but the enzyme-inhibition duration outlasts the plasma half-life significantly, meaning a missed single dose does not eliminate the suppression effect [2]. Missing more than 3 to 4 consecutive days would allow DHT to begin recovering toward baseline.

Take the pill at the same time each day to build the habit, not because pharmacokinetics demand it.

Photography Protocol

Standardized baseline photography is the most useful month-one action after simply starting the drug. Use consistent overhead lighting (a ring light or bathroom overhead), the same camera-to-scalp distance (approximately 30 cm), and photograph at minimum three angles: crown, frontal hairline, and temporal recession. Store dated files. No clinical endpoint at month one justifies a treatment decision, but having those photos at month 6 or 12 will clarify whether your response matches trial data.

When to Contact Your Prescriber

Call within month one if you experience:

• Breast tissue growth or nipple tenderness
• Persistent testicular pain
• Rash or allergic reaction
• Sexual side effects that concern you, even if mild
• Shedding that exceeds approximately 200 hairs per day or involves large clumps

Do not stop the medication based on shedding alone without consulting your provider. Abrupt discontinuation resets DHT suppression within 14 days and restarts the follicle miniaturization process [2].

Lab and Monitoring Benchmarks

The American Urological Association recommends obtaining a baseline PSA before starting finasteride in men over 40, and adjusting all future PSA values by multiplying by 2.0 to correct for the drug's suppressive effect [4]. Younger men without prostate cancer risk factors do not universally require baseline PSA, but it is good practice.

No routine bloodwork is required to monitor finasteride safety in otherwise healthy men. Liver function tests are not indicated at standard 1 mg doses based on current FDA labeling [2].

What Month One Should Not Be

Month one of finasteride is not a cosmetic result window. Expecting visible regrowth at 30 days creates unnecessary anxiety and drives premature discontinuation, which is a documented problem: a 2019 survey published in the Journal of the American Academy of Dermatology found that 38% of men who stopped finasteride did so before 6 months, most citing lack of visible results rather than side effects [11]. Those men never reached the efficacy window the clinical trials describe.

"Patients should be counseled that 6 to 12 months of continuous therapy is required before a meaningful assessment of efficacy can be made," reads the current American Academy of Dermatology AGA treatment guideline [12]. That clinical instruction is the correct frame for month one.